Study of Aspirin and Exemestane as Adjuvant Treatment in Breast Cancer

• Status: Unknown status
• Trial end date: 2014-07-01
• Target enrollment: 0
• Participant gender: Female

Summary

This is a phase II study to assess efficacy/safety of Exemestane with or without Aspirin as the adjuvant treatment in postmenopausal breast cancer patients.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Chinese Academy of Medical Sciences
• Treatments: Aspirin; Exemestane

Criteria

Inclusion Criteria:

• Breast cancer after surgery postmenopausal

Exclusion Criteria:

• contraindication of aspirin